Kind Pharmaceuticals Resolves Legal Dispute, Advances HIF-PHI Anemia Treatment
Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC, alongside their key executives Dr. Dong Liu and Dr. Shaojiang Deng, have reached a resolution in their recent conflict with FibroGen, Inc. concerning Kind Pharmaceuticals’ hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) technology. The agreement entails the withdrawal of all ongoing legal actions related to this technology by both parties, with no monetary transactions involved.
HIF-PHIs represent a promising class of compounds utilized in the treatment of anemia. Among Kind Pharmaceuticals’ developments is their HIF-PHI drug candidate, AND017, which is currently undergoing clinical trials aimed at addressing anemia in chronic kidney disease (CKD) patients. Following this settlement, Kind Pharmaceuticals retains the liberty to progress with the development of AND017 and other HIF-PHI compounds in their research pipeline.
Dr. Liu, Chief Executive Officer of Kind Pharmaceuticals, expressed satisfaction with the resolution, stating, “Kind is pleased that these disputes have been fully and finally resolved. With these disputes behind us, Kind can now focus on advancing its innovative pipeline of products to the market.”
Related posts:
Key Market Analysis of Sickle Cell Disease, Fanconi Anemia, and Diamond-Blackfan Anemia in the Inherited Types of Anemia Therapeutic Space
Mallinckrodt Pharmaceuticals: From a “New Beginning” to Legal Turmoil
NRx Pharmaceuticals Unveils pH-Neutral IV Ketamine Formulation, HTX-100, Revolutionizing Treatment
U.S. FDA Approves Akebia’s Vadadustat For CKD-induced Anemia
